ENTX

SEC source: 0001178913-26-003951 · zk2635793.xml · derivative · entry 1

Burshtein Gregory · CIK 0002026002 · Chief of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 180,000 shares

Expires 2036-05-07

F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).

SEC source: 0001178913-26-003950 · zk2635792.xml · derivative · entry 2

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 200,000 shares

Expires 2036-08-07

F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was originally approved by the Board on July 15, 2022, subject to (i) approval by the Company's shareholders, which was obtained on September 7, 2022, (ii) the occurrence of a Triggering Event (as defined and specified in Ms. Toledano's employment agreement), which was satisfied upon the Company obtaining the necessary resources to fund its Phase 3 trial through the consummation of the Company's July 2026 financing transaction, and (iii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a four-year period that commenced on August 7, 2026, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-26-003950 · zk2635792.xml · derivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares

Expires 2036-05-06

F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

SEC source: 0001178913-26-003949 · zk2635791.xml · derivative · entry 3

Germano Geno J · CIK 0001424383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,014

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 43,014 shares

Expires 2036-05-07

F3 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 4, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

SEC source: 0001178913-26-003949 · zk2635791.xml · derivative · entry 2

Germano Geno J · CIK 0001424383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 50,000 shares

Expires 2036-05-07

F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 4, 2026, with one-third of the options vesting on February 4, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

SEC source: 0001178913-26-003949 · zk2635791.xml · nonDerivative · entry 1

Germano Geno J · CIK 0001424383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,014

F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

SEC source: 0001178913-26-003957 · zk2635885.xml · derivative · entry 3

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,405

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 43,405 shares

Expires 2036-05-07

F3 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest on a quarterly basis over a one-year period that began on February 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

SEC source: 0001178913-26-003957 · zk2635885.xml · derivative · entry 2

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,368

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,368 shares

Expires 2036-05-07

F2 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on February 1, 2026, with one third of the options vesting on February 1, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

SEC source: 0001178913-26-003957 · zk2635885.xml · nonDerivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,117

F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

SEC source: 0001178913-26-003956 · zk2635884.xml · nonDerivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,231

F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

SEC source: 0001178913-26-003955 · zk2635883.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,269

F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

SEC source: 0001178913-26-003954 · zk2635796.xml · derivative · entry 2

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 40,000 shares

Expires 2036-05-07

F2 · shares: Represents a grant of fully vested options to purchase ordinary shares. This grant of options was approved by the Board on May 7, 2026, subject to (i) approval by the Company's shareholders, which was obtained on July 14, 2026 and (ii) the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026.

SEC source: 0001178913-26-003954 · zk2635796.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,132

F1 · kind: The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

SEC source: 0001178913-26-003953 · zk2635795.xml · derivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 140,000 shares

Expires 2036-05-07

F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).

SEC source: 0001178913-26-003952 · zk2635794.xml · derivative · entry 1

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 200,000 shares

Expires 2036-05-07

F1 · derivative.exercise_date: Represents a grant of options to purchase ordinary shares. This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the ordinary shares underlying the option grant, which occurred on August 7, 2026. The options vest over a three year period which began on May 7, 2026, with one third of the options vesting on May 7, 2027 and the remaining two-thirds vesting ratably on a quarterly basis over the remaining two-year period, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan).

SEC source: 0001178913-26-003508 · zk2635690.xml · nonDerivative · entry 2

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 847,135

F2 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2026. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Plan).

SEC source: 0001178913-26-003508 · zk2635690.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 774,142

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026, subject to approval by the Company's shareholders, which was obtained on July 14, 2026. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2025 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026, subject to full acceleration upon a Change in Control (as defined in the Company's 2018 Equity Incentive Plan (the "Plan")).

SEC source: 0001178913-26-002462 · ownership.xml · nonDerivative · entry 1

Burshtein Gregory · CIK 0002026002 · Chief of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 189,033

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

SEC source: 0001178913-26-002466 · ownership.xml · nonDerivative · entry 1

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,566

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

SEC source: 0001178913-26-002464 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 171,441

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on May 7, 2026. This grant was awarded to the Reporting Person in lieu of a cash bonus the Reported Person was otherwise entitled to. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on May 1, 2026.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-26-000825 · ownership.xml · nonDerivative · entry 1

Germano Geno J · CIK 0001424383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

SEC source: 0001178913-26-000787 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,098

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2287 to $1.245 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001178913-26-000508 · zk2634371.xml · nonDerivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

SEC source: 0001178913-26-000413 · ownership.xml · nonDerivative · entry 1

Germano Geno J · CIK 0001424383 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

SEC source: 0001178913-26-000414 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: Not disclosed

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.4799 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001178913-26-000412 · zk2634333.xml · nonDerivative · entry 1

Rubin Steven D · CIK 0001381874 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

SEC source: 0001178913-26-000411 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,098

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.299 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001178913-26-000016 · ownership.xml · derivative · entry 6

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,505

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares

Expires 2036-01-01

F3 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

SEC source: 0001178913-26-000016 · ownership.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,454

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

SEC source: 0001178913-26-000020 · ownership.xml · derivative · entry 2

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,505

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares

Expires 2036-01-01

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

SEC source: 0001178913-26-000020 · ownership.xml · nonDerivative · entry 1

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,657

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

SEC source: 0001178913-26-000018 · ownership.xml · derivative · entry 2

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,505

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares

Expires 2036-01-01

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

SEC source: 0001178913-26-000018 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,098

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

SEC source: 0001178913-26-000017 · ownership.xml · derivative · entry 2

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,505

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares

Expires 2036-01-01

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

SEC source: 0001178913-26-000017 · ownership.xml · nonDerivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,416

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

SEC source: 0001178913-26-000015 · ownership.xml · derivative · entry 2

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,505

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,505 shares

Expires 2036-01-01

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2026.

SEC source: 0001178913-26-000015 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,979

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the 2025 fiscal year.

SEC source: 0001178913-25-004125 · ownership.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 426,575

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.82, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001178913-25-002412 · ownership.xml · derivative · entry 2

Burshtein Gregory · CIK 0002026002 · Chief of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 200,000 shares

Expires 2035-04-28

F2 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-25-002412 · ownership.xml · nonDerivative · entry 1

Burshtein Gregory · CIK 0002026002 · Chief of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,442

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

SEC source: 0001178913-25-002414 · zk2533456.xml · derivative · entry 3

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares

Expires 2035-04-28

F3 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-25-002414 · zk2533456.xml · nonDerivative · entry 2

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 415,575

F2 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of $100,000 the Reporting Person is entitled to under the Reporting Person's base salary for 2025. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 1, 2025.

SEC source: 0001178913-25-002414 · zk2533456.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,715

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

SEC source: 0001178913-25-002410 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2035-04-28

F3 · derivative.exercise_date: This grant of options was approved by the Board on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. The options vest over a three-year period that commenced on April 28, 2025, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-25-002410 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 113,047

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 28, 2025, subject to approval by the Company's shareholders, which was obtained on July 16, 2025. This grant was awarded to the Reporting Person in lieu of the Reporting Person's 2024 annual cash bonus. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

F2 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-25-001539 · ownership.xml · derivative · entry 2

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 100,000 shares

Expires 2025-04-28

F2 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 28, 2025, the first anniversary of the vesting commencement date, and the remaining options vesting ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-25-001539 · ownership.xml · nonDerivative · entry 1

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,573

F1 · price: Represents a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 28, 2025.

SEC source: 0001178913-25-001192 · ownership.xml · derivative · entry 6

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares

Expires 2028-12-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001178913-25-001192 · ownership.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001178913-25-000156 · ownership.xml · derivative · entry 6

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares

Expires 2035-01-15

F6 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.